Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : AtheroGenics, Inc.{AGIX}-nasdaq -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (193)	5/1/2006 8:50:24 AM
From: kenhott	Respond to of 332

I have been out myself, just back last night. I need a vacation from my vacation. <The event rate has come down from 15% to 8%..> Previous guidance: The ARISE protocol initially targeted 4,000 patients for enrollment who were to be followed for a minimum of 12 months or until at least 1,160 primary events occurred. The 4,000 patient mark was reached in November 2004. Due to lower than originally anticipated clinical events, and in an effort to enhance and accelerate the pace of the trial, the Company petitioned the U.S. Food and Drug Administration (FDA) to increase the sample size to 6,000 patients, eliminate the minimum 12-month follow-up period and decrease the target number of primary events to 990. This revised target number will continue to yield greater than 95 percent statistical power to detect a 20 percent difference in clinical events between the patients taking AGI-1067 and those patients on standard of care alone. In February, 2005 the FDA approved all of our proposed changes. In the summer of 2005 we completed ARISE enrollment with approximately 6,127 patients enrolled in the study. We anticipate announcing topline results from ARISE in early 2007. This drop in event rates if true is in my opinion not good for AGIX on balance. I had closed my long position for like a whole 50 cents. That was exciting.